Abstract | AIMS AND BACKGROUND: METHODS: RESULTS: Thirty-eight patients were treated with radiation therapy. Their median age was 51.5 years. Most patients were FIGO stage III (27/38) with serous adenocarcinoma (26/38). All patients had received at least one regimen of platinum-based chemotherapy; 24 patients were sensitive to the first chemotherapy and the others were resistant. Lymph node and abdominopelvic wall were the most common sites of radiation therapy. The response rate was 65.0% (16 complete remissions and 10 partial remissions), and the median regression rate was 78.8% (range, -66.6 to 100.0). Median progression-free survival was 7.2 months (range, 1.0-66.6). In 28 patients who had a solitary relapsed site from the radiographic finding at the time of radiation therapy, it was 10.7 months (range, 1.8-66.6). Neither hematologic nor intestinal toxicity of grade 3-4 was observed. Prognostic factors were sensitivity to platinum and the site treated with radiation therapy. CONCLUSIONS:
|
Authors | Shin-Wha Lee, Sang-Min Park, Yong-Man Kim, Young-Seok Kim, Eun-Kyung Choi, Dae-Yeon Kim, Jong-Hyeok Kim, Joo-Hyun Nam, Young-Tak Kim |
Journal | Tumori
(Tumori)
2011 Sep-Oct
Vol. 97
Issue 5
Pg. 590-5
ISSN: 2038-2529 [Electronic] United States |
PMID | 22158489
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cystadenocarcinoma, Serous
(drug therapy, radiotherapy, secondary)
- Disease-Free Survival
- Dose Fractionation, Radiation
- Female
- Humans
- Kaplan-Meier Estimate
- Lymph Nodes
(pathology, radiation effects)
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Recurrence, Local
(radiotherapy)
- Neoplasm Staging
- Ovarian Neoplasms
(drug therapy, pathology, radiotherapy)
- Platinum Compounds
(administration & dosage)
- Radiotherapy, Adjuvant
- Republic of Korea
- Retrospective Studies
- Treatment Outcome
|